Swedish Orphan Biovitrum AB





Market Closed - Nasdaq Stockholm 11:29:47 2024-02-29 am EST 5-day change 1st Jan Change
254.6 SEK +0.47% Intraday chart for Swedish Orphan Biovitrum AB -4.00% -4.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sobi to Expand in South Korea via Rare Disease JV with Handok MT
US Futures, European Stocks Mixed DJ
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox CI
Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says MT
Transcript : Swedish Orphan Biovitrum AB, Q4 2023 Earnings Call, Feb 08, 2024
Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024 CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sobi's Profit to Get Royalty Boost as Sanofi Partnerships Outperform, RBC Says MT
Ericsson: new CFO in early April CF
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health... Our Logo
Swedish Orphan Chairman Steps Down, Successor Named MT
Swedish Orphan Biovitrum AB Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member CI
Nordic Shares Closed Up Thursday; Schibsted Series B Topped Leaders DJ
AstraZeneca prioritizes US for RSV drug amid surge in cases RE
Swedish Orphan Biovitrum Completes Issuance, Repurchase of Convertible Shares MT
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement CI
Transcript : Swedish Orphan Biovitrum AB, Q3 2023 Earnings Call, Oct 30, 2023
European shares rise as bond yields retreat; Siemens Energy jumps RE
Swedish Orphan Biovitrum AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G CI
Recordati, Zdravkovic vice president R&D and Sabia new CMO AN
Swedish Orphan Biovitrum Makes Interim Chief Medical Officer Permanent MT
Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer CI
Chart Swedish Orphan Biovitrum AB
More charts
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company's product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
254.6 SEK
Average target price
317.9 SEK
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Swedish Orphan Biovitrum AB - Nasdaq Stockholm
  4. News Swedish Orphan Biovitrum AB
  5. Sweden's Sobi to Buy Hematology-focused CTI Biopharma for $1.7 Billion
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.